Neuland Laboratories Reports Q3FY26 Total Income at Rs.1264.5 crore, EBITDA at Rs.284 crore

Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, announced financial results for the quarter ended December 31, 2025. The company reported a total income of Rs.1264.5 crore and EBITDA of Rs.284 crore. Despite the revenues being in line with the outlook, the product mix and increased operating expenses led to subdued EBITDA margins. The company is seeing increasing interest from customers for its commercial NCE drug substance manufacturing and innovation journey capabilities.